Analysts Set Immunome, Inc. (NASDAQ:IMNM) PT at $33.17

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $33.1667.

IMNM has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Craig Hallum increased their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Truist Financial increased their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Leerink Partners lowered their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Stephens lowered their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th.

Insider Activity at Immunome

In related news, Director Philip Wagenheim sold 28,200 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $582,330.00. Following the sale, the director directly owned 341,147 shares of the company’s stock, valued at $7,044,685.55. This trade represents a 7.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jack Higgins sold 9,438 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the sale, the insider directly owned 22,000 shares in the company, valued at $476,080. This represents a 30.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 139,438 shares of company stock valued at $2,964,664. Company insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after purchasing an additional 14,398 shares in the last quarter. Creative Planning purchased a new stake in Immunome in the second quarter valued at approximately $167,000. Rhumbline Advisers raised its stake in Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after purchasing an additional 19,526 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Immunome by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after acquiring an additional 9,686 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Immunome during the second quarter valued at approximately $1,021,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Trading Up 0.2%

Shares of Immunome stock opened at $18.61 on Thursday. Immunome has a 12-month low of $7.96 and a 12-month high of $27.65. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -7.82 and a beta of 2.04. The company’s 50-day moving average price is $21.97 and its 200-day moving average price is $21.70.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, sell-side analysts predict that Immunome will post -2.06 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.